Catalyst Pharmaceuticals appoints Tamar Thompson to its board of directors

CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (\”Catalyst\” or Company) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on the licensing, development and commercialization of new drugs for rare disease patients, today announced the appointment of Ms. Tamar Thompson to the Company\’s Board of Directors (\”Board\”), effective May 25, 2023.

“We are extremely pleased to welcome Tamar to our board as she brings extensive experience to our team across multiple therapeutic categories, including rare diseases, along with broad health policy and government business acumen,” he said. Patrick J. McEnany, President and CEO of Catalyst. “Ms. Thompson\’s distinguished industry experience and leadership align ideally with Catalysts\’ long-term growth strategy. We look forward to her valuable contributions as we continue to advance our expansion initiatives to deliver innovative medicines for rare neurosciences to more patients seeking new treatment options.\”

\”I am honored to join the Catalyst Board at such a pivotal moment in the company\’s history,\” said Ms. Thompson. “Catalyst has experienced a very successful evolution over the past few years and is well positioned to further capitalize on its established capabilities with additional new assets that complement its growing product portfolio. I look forward to working with the board and Catalyst\’s leadership team as the company moves forward with its strategic growth plans.\”

Ms. Thompson has more than twenty years of healthcare industry leadership experience, health policy strategy, government affairs and market access, with a diverse background in multiple healthcare sectors and therapeutic categories, including rare diseases, with a focus on development strategic and tactical recommendations to ensure optimal reimbursement and market access for rare disease products. Ms. Thompson currently serves as Vice President, Head of Global Corporate Affairs for Alexion Pharmaceutical, AstraZeneca Rare Diseases. Prior to joining Alexion, Ms. Thompson served as Executive Director, State Government Affairs and Federal Policy for Bristol-Myers Squibb Company. Prior to joining Bristol Myers Squibb, she served as a strategic policy advisor and consultant for various government affairs firms based in Washington, DC

The story continues

Ms. Thompson holds a Master of Science in Health Sciences with an emphasis in Public Health from Trident University in Cypress, California and currently serves on the Board of Directors of Avidity Biosciences.

About Catalyst Pharmaceuticals
With exceptional patient focus, Catalyst is committed to developing and commercializing first-in-class innovative medicines that address rare neurological and epileptic diseases. Catalyst\’s flagship commercial product in the United States is FIRDAPSE ^{(amifampridine) 10 mg tablets, approved for the treatment of Lambert-Eaton myasthenic syndrome (\”LEMS\”) for adults and children aged six to seventeen years. In January 2023, Catalyst acquired the US commercial rights to FYCOMPA (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four years and older alone or with other medicines for the treatment of partial-onset seizures with or without secondary generalized seizures and with other medicines for the treatment of tonic seizures -primary generalized clonic for people with epilepsy aged 12 and over. In addition, Canada\’s national health regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.}

For complete prescribing and safety information for FIRDAPSE^{please visit www.firdapse.com. For complete prescribing information, including boxed WARNINGS for FYCOMPAplease visit www.fycompa.com. For more information about Catalyst Pharmaceuticals, Inc., visit the company\’s website at www.catalystpharma.com.}

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which could cause actual results of Catalyst in future periods to differ materially from anticipated results. A number of factors, including those described in Catalyst\’s annual report on Fiscal Year 2022 Form 10-K and other filings with the United States Securities and Exchange Commission (\”SEC\”), could adversely affect Catalyst. Copies of Catalyst\’s SEC filings are available with the SEC, they can be found at Catalyst websiteor can be obtained upon request from Catalyst. Catalyst undertakes no obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

CONTACT: Investor Relations Contact: Mary Coleman Catalyst Pharmaceuticals (305) 420-3200 mcoleman@catalystpharma.com Media Contact: David Schull Russo Partners (858) 717-2310 david.schull@russopartnersllc.com